14 Facts About GAVI

GAVI, officially Gavi, the Vaccine Alliance is a public–private global health partnership with the goal of increasing access to immunization in poor countries.

GAVI seeks to design its AMCs in a way that encourages a competitive market.

GAVI has been particularly successful at promoting the uptake of newer vaccines.

Advance Market Commitment had transferred far more money to GSK and Pfizer than the GAVI grants had transferred to low-cost suppliers for technology transfer and product development.

The duopoly allowed price discrimination; apart from charging slightly higher prices for GAVI, it charged unaffordable prices for middle-income countries too rich for GAVI aid.

Related searches

GAVI responded by agreeing with MSF's goals, but regretting that MSF had discussed the issue in public as well as through its own close ties to GAVI.

GAVI said that low prices required large, stable, high-volume deals, and "careful consideration and the support of key constituencies".

At GAVI, some argued that vaccination could not be effectively carried out and sustained without strengthening healthcare, citing experiences in Gavi's vaccination programmes, where availability of staff, training, transport, and funds had hindered vaccination and reporting of vaccination coverage and stocks.

Such criticisms were generally not a topic that GAVI engaged with internally; the lack of internal engagement with the issue has been criticized.

GAVI measured HSS using vaccination coverage as the sole indicator.

GAVI subsequently shifted HSS aid to focus more on sustainability and the principles of the Paris Declaration for Aid Effectiveness.

GAVI spent 15 years with a program for shaping the pentavalent vaccine market to be more stable and competitive.

GAVI advocated that the pandemic needed a global response whereby the best global facilities for separate parts of the processes should then be integrated into a global process.

GAVI said he hoped that the G20 countries should work together with a budget of tens of billions of dollars, and that individual countries should be prepared for finished vaccines to be allocated according to greatest need.